Skip to main content
. 2021 Jan 19;11(7):3439–3451. doi: 10.7150/thno.53561

Figure 1.

Figure 1

NL101 inhibits the growth of B cell lymphoma in vitro and in vivo. A. Nine B cell lymphoma cell lines were incubated with indicated concentrations of NL101 for 48 h, and the viability was analyzed by MTT assay. B. IC50 of NL101 on primary cells from 3 healthy volunteers (left; red dots) and 5 patients with B cell lymphoma (right; green square represents the sample from the pleural fluid of a DLBCL patient; yellow square represents the sample extracted from the ascites of a DLBCL patient; blue squares are samples from 3 CLL patients' peripheral blood). C. Mice bearing subcutaneous Ramos xenograft were randomized to receive PBS (control) and NL101 (15 mg/kg, iv, every other day for 2 weeks), respectively, tumor volumes were calculated every other day. *, P < 0.05; **, P < 0.01; ***, P < 0.001. D. Images of mice and corresponding tumors of control and NL101 groups. E. Survival of mice xenograft model analyzed with a Kaplan-Meier curve.